Multi-target inhibitors in non-small cell lung cancer (NSCLC)

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Tiseo, M ^a   Franciosi, V ^a   Ardizzoni, A ^a  

^a Azienda Ospedaliera Universitaria   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; EDEMA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IC 50; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUTH PAIN; NONHUMAN; PAIN; PRIORITY JOURNAL; QT PROLONGATION; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SKIN TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDOLES; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33645812143     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj924     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Carney DN. Lung cancer-time to move on from chemotherapy. N Engl J Med 2002; 346: 126-128.
3. Sheperd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
4. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 2005, 23: 2s (Abstr no. 4).
5. Tiseo M, Loprevite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer. Curr Med Chem Anti-Canc Agents 2004; 4 (2): 139-148.
6. Janne PA, Engelman JA and Johnson BE. Epidermal growth factor receptor mutations in non-small cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-3234.
7. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/Epidermal Growth Factor Receptor tyrosine kinase inhibitor erlotinib for patients with recurrent Non-Small-Cell Lung Cancer. J Clin Oncol 2005, 23: 2544-2555.
8. Herbst RS. Role of novel targeted therapies in the clinic. Br J Cancer 2005; 92 (Suppl 1): S21-S27.
9. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92 (Suppl 1): S7-S13.
10. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
11. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-1556.
12. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-793.
13. Heymach JV. ZD6474 - clinical experience to date. Br J Cancer 2005; 92 (Suppl 1): S14-S20.
14. Natale R, Bodkin D, Govindan R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa™) in patients with NSCLC: results of a randomized, double blind phase II study. Lung Cancer 2005; 49 (Suppl 2): S37 (Abstr O-103).
15. Heymach J, West H, Kerr R et al. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study. Lung Cancer 2005; 49 (Suppl 2): S247 (Abstr. P-497).
16. Herbst RS, Johnson B, Rowbottom J et al. ZD6474 plus docetaxel with previously treated NSCLC: Results of a randomized, placebo-controlled phase II trial. Lung Cancer 2005; 49 (Suppl 2): S35 (Abstr. O-100).
17. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
18. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
19. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; (Published ahead of print on November 28, 2005 as 10.1200/JCO.2005.02.2194.)
20. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases Involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
21. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472-5480.
22. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
23. Adjei AA, Mandrekar S, Marks RS et al. A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol 2005; 23: 208S (Abstr. 3067).